Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
GM1 dose-ranging study for prevention of VRD-induced neurotoxicity in multiple myeloma
ChiCTR2000041283Phase 4Recruiting
- Sponsor
- Harbin Medical University Cancer Hospital
- Start
- May 2020
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 4, open-label trial of monosialotetrahexosylganglioside in chemotherapy-induced peripheral neuropathy (CIPN) (4 arms), sponsored by Harbin Medical University Cancer Hospital. Primary endpoint: Total Neuropathy Score (TNS). Started May 2020; status: recruiting.
02
Drugs
monosialotetrahexosylganglioside
03
Conditions
chemotherapy-induced peripheral neuropathy (CIPN)
Beyond the preview
Go deeper on ChiCTR2000041283.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2000041283.